In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Cipla Limited

Generics And Biosimilars Industry Reshaped By Transformations

The latest Generics Bulletin Top 50 ranking of global generics and biosimilars companies sees a new name in the top five amid transformations for some of the leading off-patent players. Meanwhile, a number of mid-level firms shift position and newcomers climb into the bottom of the table.

Outlook 2023 Generic Drugs

Big Pharma Restructures Commercial Teams In India

More foreign pharma firms, this time Sanofi and GSK, are reorganizing sales and marketing efforts accompanied by layoffs in India. Scrip talks to experts about what’s driving the right-sizing and the wider trend.

India Commercial

Zydus Sees Revlimid Generic Revenues Beyond Q4 As It Waits For Antitrust Suit To Play Out

Zydus, along with Bristol Myers Squibb and generics companies like Mylan, Cipla and Dr. Reddy’s, has been named in an antitrust suit involving BMS’ blockbuster drug Revlimid. For now, it expects revenues from the generic to stretch beyond Q4 FY’23. Meanwhile, a recent acquisition of Watson, which made APIs for the Teva group, should shore up declining API revenues

Commercial Business Strategies

Alembic Straddles Oversupply And Shortages In US

One-off opportunities lift Alembic’s US generics business in the fiscal second quarter but the market continues to pose challenges amid surging oversupply and price erosion. On the other hand, a string of injectable approvals, including for ketorolac tromethamine, could open up opportunities for the company given the 'on and off' shortages.

Sales & Earnings Generic Drugs
See All

Company Information

  • Industry
  • Contract Research Organization-CRO
  • Medical Devices
  • Pharmaceuticals
  • Services
    • Consulting Services
  • Pharmaceuticals
    • Drug Delivery
    • Generic Drugs
    • Nutraceuticals
    • Vaccines
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Other Names / Subsidiaries
    • Cipla Gulf FZ LLC
    • Cipla Technologies LLC
    • InvaGen Pharmaceuticals Inc.
    • Mirren Pty, Ltd.
UsernamePublicRestriction

Register